AbbVie Inc. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
AbbVie Inc. (ABBV) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $337.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-02-20
- AbbVie Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $337.00M, a 94.80% increase from fiscal 2024.
- AbbVie Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $173.00M, a 34.11% increase from fiscal 2023.
- AbbVie Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $129.00M, a 46.59% increase from fiscal 2022.
- AbbVie Inc. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $88.00M, a 57.69% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $337.00M 10-K · filed 2026-02-20 |
| 2024-12-31 | $173.00M 10-K · filed 2026-02-20 |
| 2023-12-31 | $129.00M 10-K · filed 2026-02-20 |
| 2022-12-31 | $88.00M 10-K · filed 2025-02-14 |
| 2021-12-31 | $208.00M 10-K · filed 2024-02-20 |
| 2020-12-31 | $91.00M 10-K · filed 2023-02-17 |
| 2019-12-31 | $113.00M 10-K · filed 2022-02-18 |
| 2018-12-31 | $163.00M 10-K · filed 2021-02-19 |
| 2017-12-31 | $1.77B 10-K · filed 2020-02-21 |
| 2016-12-31 | $118.00M 10-K · filed 2019-02-27 |
| 2015-12-31 | $187.00M 10-K · filed 2018-02-16 |
| 2014-12-31 | $115.00M 10-K · filed 2017-02-17 |
| 2013-12-31 | $195.00M 10-K · filed 2016-02-19 |
| 2012-12-31 | $370.00M 10-K · filed 2015-02-20 |
| 2011-12-31 | $294.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |